ArticleJournal of virology2022
The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus.
Open access · greenAbstract read
In one paragraph
Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 1 pooled it
10.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- The Reassessed Potential of SARS-CoV-2 Attenuation for COVID-19 Vaccine Development-A Systematic Review.Viruses · 2022Pooled it
- Identification of HIF1A as a therapeutic target during SARS-CoV-2-associated lung injury.JCI insight · 2025Trial
- Exposure route, not dose, is the primary driver of infection patterns for a respiratory virus.Science advances · 2026Article
- Pathogenicity Difference Between Male and Female mice by Recent SARS-CoV-2/2025.Current microbiology · 2026Article
- Revisiting endothelial tropism of SARS-CoV-2 using a cell-specific hACE2 mouse model.Microbiology spectrum · 2026Article
- Megakaryocytes Internalize and Are Activated by Immune Complexes.Circulation research · 2026Article
- Exacerbated Hepatic Stress and Systemic Metabolic Disruption Driven by SARS-CoV-2 P.1 Variant in K18-hACE2 Mice.Immunity, inflammation and disease · 2026Article
- Exploring coronavirus cell entry with functional viromics.Journal of virology · 2026Review
- SARS-CoV-2 virus infection ofbioRxiv : the preprint server for biology · 2026Article
- SARS-CoV-2 Effects on Respiratory and Neurological Systems: Morphological Findings and Gene Expression in K18-hACE2 Mice Model.Microorganisms · 2026Article
- Exposure route drives SARS-CoV-2 infection patterns in non-human primates.bioRxiv : the preprint server for biology · 2026Article
- Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant.The Journal of general virology · 2026Article
- A Modular Vaccine Platform Against SARS-CoV-2 Based on Self-Assembled Protein Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A bireporter recombinant SARS-CoV-2 Omicron BA.5 forbioRxiv : the preprint server for biology · 2026Article
- Ultrastructural Features, Immune Response, and Junctional Proteins in the Seminiferous Epithelium of SARS-CoV-2-Infected Mice.International journal of molecular sciences · 2026Article
- The Role of Keratin in the Mechanisms of Kidney Diseases.BioMed research international · 2026Review
- Article
- Neuroinflammatory and transcriptional dynamics during SARS-CoV-2 infection in KRT18-hACE2 mouse brain.Frontiers in immunology · 2026Article
- Structural Design and Immunogenicity of a Novel Self-Adjuvanting Mucosal Vaccine Candidate for SARS-CoV-2 Expressed in Plants.Plant biotechnology journal · 2026Article
- Cardiac Tissue Damage in a Female Animal Post-COVID Model: Relevance of Chemokine-Mediated Inflammation.Viruses · 2025Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 1 country.
Wenjuan Dong *Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Heather Mead *Pathogen and Microbiome Institute, Northern Arizona Universitygrid.261120.6, Flagstaff, Arizona, USA.
Lei TianDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Jun-Gyu ParkDisease Intervention and Prevention, and Population Health Programs, Texas Biomedical Research Institutegrid.250889.e, San Antonio, Texas, USA.
Juan I GarciaDisease Intervention and Prevention, and Population Health Programs, Texas Biomedical Research Institutegrid.250889.e, San Antonio, Texas, USA.
Sierra JaramilloPathogen and Microbiome Institute, Northern Arizona Universitygrid.261120.6, Flagstaff, Arizona, USA.
Tasha BarrDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Daniel S KollathPathogen and Microbiome Institute, Northern Arizona Universitygrid.261120.6, Flagstaff, Arizona, USA.
Vanessa K CoynePathogen and Microbiome Institute, Northern Arizona Universitygrid.261120.6, Flagstaff, Arizona, USA.
Nathan E StonePathogen and Microbiome Institute, Northern Arizona Universitygrid.261120.6, Flagstaff, Arizona, USA.
Ashley JonesPathogen and Microbiome Institute, Northern Arizona Universitygrid.261120.6, Flagstaff, Arizona, USA.
Jianying ZhangDepartment of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California, USA.
Aimin LiPathology Core, Shared Resources, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
Li-Shu WangDivision of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Martha Milanes-YearsleyDepartment of Pathology, The Ohio State University, Columbus, Ohio, USA.
Jordi B TorrellesDisease Intervention and Prevention, and Population Health Programs, Texas Biomedical Research Institutegrid.250889.e, San Antonio, Texas, USA.
Luis Martinez-SobridoDisease Intervention and Prevention, and Population Health Programs, Texas Biomedical Research Institutegrid.250889.e, San Antonio, Texas, USA.ORCID 0000-0001-7084-0804
Paul S KeimPathogen and Microbiome Institute, Northern Arizona Universitygrid.261120.6, Flagstaff, Arizona, USA.ORCID 0000-0003-0089-5820
Bridget Marie BarkerPathogen and Microbiome Institute, Northern Arizona Universitygrid.261120.6, Flagstaff, Arizona, USA.
Michael A CaligiuriDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
Jianhua YuDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.ORCID 0000-0002-0326-3223
Northern Arizona University · USCity Of Hope National Medical Center · USTexas Biomedical Research Institute · USCity of Hope · USMedical College of Wisconsin · USThe Ohio State University · US
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MThe Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI KEITH LLOYD LIGON · 2013 to 2026
$26.0MHuman natural killer cells: Advancing biology and clinical applicationsR35CA210087 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2017 to 2026
$8.3MThe origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5MCharacterizing and Targeting the Novel IL-15- AKT-XBP1s Pathway in NK CellsR01CA247550 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI YU, JIANHUA · 2020 to 2024
$2.2MElucidate and Modulate Cell Signaling in NK Cells for Glioma TreatmentR01AI129582 · NIAID · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2017 to 2021
$2.1MOvercoming Barriers of Virotherapy by Next-Generation oHSV Expressing E-CadherinR01NS106170 · NINDS · OHIO STATE UNIVERSITY · PI YU, JIANHUA · 2018 to 2023
$1.9MscFvPD1-FLT3 CAR T Cells for the Treatment of Relapsed Acute Myeloid LeukemiaR21CA223400 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI YU, JIANHUA · 2019 to 2020
$414kSMALL INSTRUMENTATION GRANTS15AG011947 · NIA · HEBREW HOME OF GREATER WASHINGTON · PI COHEN-MANSFIELD, JISKA · 1993 to 1993
–California Institute for Regenerative Medicine DISC2COVID19-11947HHS | NIH | National Cancer Institute (NCI) CA163205HHS | NIH | National Cancer Institute (NCI) CA210087HHS | NIH | National Cancer Institute (NCI) CA223400HHS | NIH | National Cancer Institute (NCI) CA247550HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI129582HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) NS106170Leukemia and Lymphoma Society (LLS) 1364-19NCI NIH HHS P01 CA163205NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA247550NCI NIH HHS R21 CA223400NCI NIH HHS R35 CA210087NIAID NIH HHS R01 AI129582NINDS NIH HHS R01 NS106170
Abstract
A comprehensive analysis and characterization of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection model that mimics non-severe and severe coronavirus disease 2019 (COVID-19) in humans is warranted for understating the virus and developing preventive and therapeutic agents. Here, we characterized the K18-hACE2 mouse model expressing human (h)ACE2 in mice, controlled by the human keratin 18 (K18) promoter, in the epithelia, including airway epithelial cells where SARS-CoV-2 infections typically start. We found that intranasal inoculation with higher viral doses (2 × 10
Indexed as
Disease Models, AnimalAngiotensin-Converting Enzyme 2AnimalsCOVID-19HumansImmune SeraKeratin-18MiceMice, TransgenicPromoter Regions, GeneticReinfectionSARS-CoV-2Viral ProteinsACE2 protein, humanAngiotensin-Converting Enzyme 2Immune SeraKeratin-18KRT18 protein, humanViral ProteinsCOVID-19infectious diseaseK18-hACE2lung infectionmouse modelSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.